Is NCT06660732 recruiting in Rochester, MN?

Yes, NCT06660732 is currently recruiting participants at its Rochester, MN location. This cardiac sarcoidosis clinical trial is actively enrolling qualified participants.

How do I join the cardiac sarcoidosis clinical trial in Rochester?

To join this clinical trial in Rochester, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Rochester clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Cardiac Sarcoidosis Clinical Trial in Rochester, MN

Who Can Participate

Inclusion Criteria

Able to comprehend and willing to sign an ICF and to abide by the study restrictions and requirements

Age ≥ 18 years and ≤ 80 years

Female subjects must be:

postmenopausal, defined as at least 12 months post cessation of menses (without an alternative medical cause), or

permanently sterile following documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation, or having a male partner with vasectomy as affirmed by the subject, or

nonpregnant, nonlactating, and having agreed to use an effective method of contraception (i.e., hormonal contraception, intrauterine device \[IUD\], or double barrier methods such as condom plus diaphragm or diaphragm plus spermicide or condom plus spermicide) from Screening Visit 1 until 5 months after study drug administration, if sexually active.

Male subjects must have documented vasectomy or must use double barrier methods of contraception (such as condom plus diaphragm or diaphragm plus spermicide or condom plus spermicide) or use condoms plus hormonal contraceptives or condoms plus IUD with their female partners of childbearing potential from randomization to 3 months after the last dose of study drug administration. Male subjects must agree to refrain from donating sperm during this time period.

Routine adult vaccinations should be up to date and/or offered at least 2 weeks prior to randomization according to regional and national guidelines based on medical history or presence of risk factors, in the opinion of the Investigator. Cardiac Inclusion Criteria:

Has a diagnosis of cardiac sarcoidosis by the Heart Rhythm Society (HRS) expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis, or the Japanese Circulation Society 2016 Guideline on diagnosis and treatment of cardiac sarcoidosis (Terasaki 2019)

Three or more segments of active FDG uptake on PET scan within 8 weeks of randomization, despite standard therapy

Willing to wear an ambulatory cardiac rhythm monitor at the specified timepoints

Exclusion Criteria

Unable or unwilling to provide informed consent

Weight \>380 pounds (172 kilograms)

Women who are pregnant or lactating or women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study

Planned to initiate TNF-α antagonist therapy over the course of the study.

Known claustrophobia, or difficulty completing prior PET scan procedure(s)

Left ventricular end-systolic diameter (LVESD) \> 60 mm on echocardiogram

Other systemic immune disorder(s) or other disorder(s) that require treatment with immunomodulators or immunosuppressants

Has received, or is scheduled to receive after randomization, mechanical circulatory support

Congenital, valvular, and/or coronary artery disease that could explain the severity of cardiac dysfunction

Known hypersensitivity to rilonacept (KPL-914) or to any of its excipients

Meets the following TB criteria:

History of active TB prior to screening OR

History of latent TB that was not adequately treated prior to screening OR

Signs or symptoms suggestive of active TB (e.g., new cough of \>14 days in duration or a change in chronic cough, persistent fever, unintentional weight loss, or night sweats) upon review of medical history and/or physical examination at screening OR

Recent close contact with a person with active TB OR

Positive or indeterminate Interferon Gamma Release Assay (IGRA) test results or results from another positive TB test at screening based on acceptable local clinical practice

Use of the following immunosuppressive or immunomodulatory therapies (see also Section 5.6 "Prior and Concomitant Therapy") within the timeframe prior to randomization as defined below for each drug class or category:

INCREASE in dose of existing immunosuppression/immunomodulation drug or INITIATION of new immunosuppression/immunomodulation drug in the one month prior to or ON or AFTER the date of the eligibility/baseline FDG-PET scan until the date of randomization.

Anakinra within 1 week prior to first dose of study drug; canakinumab within 8 weeks prior to the first dose of study drug; abatacept within 8 weeks prior to first dose of study drug;

TNF inhibitors within 2-8 weeks of or 5 half-lives (etanercept within 2 weeks; infliximab, certolizumab, golimumab, or adalimumab within 8 weeks) prior to first dose of study drug, whichever is longer.

Rituximab within 6 months prior to the first dose of study drug unless levels of CD20+ B cells have been assessed and have returned to normal.

Cyclosporine A (CsA) within 4 weeks prior to the first dose of study drug.

Received any investigational product within 30 days or 5 half-lives (if the half-life is known) of an investigational product (whichever is longer) prior to first dose of study drug

Concurrent enrollment in another clinical study, with the exception of observational studies

Uncontrolled hypertension (systolic blood pressure \>170 mmHg and diastolic blood pressure \>110 mmHg

Uncontrolled thyroid disease (serum TSH \< 0.1 mU/L or \> 10 mU/L)

Uncontrolled diabetes mellitus (serum glucose \> 180 mg/dL fasting or HbA1c \>9%)

Estimated glomerular filtration rate (eGFR) \<30mL/min

Major surgery within 8 weeks prior to screening or planned major surgery within 6 months after first dose of study drug.

Transplanted organs (except corneal transplant performed more than 3 months prior to first dose of study drug).

Severe active, recurrent, or chronic infection (per PI discretion), or any episode of infection requiring hospitalization or treatment with a course of IV antibiotics within 12 weeks before screening. Subjects with a history of severe opportunistic infection (per PI discretion) are also excluded from the study.

High risk of infection (e.g., history of hereditary or acquired immune deficiency disorder), a history of an infected joint prosthesis at any time with that prosthesis still in situ, leg ulcers, indwelling urinary catheter, or persistent or recurrent chest infections.

Chronic active HBV infection, defined as:

HBV surface antigen positive

HBV anti-core antibody positive but anti-surface antibody negative

Presence of symptoms indicative of COVID-19 infection (per PI discretion), unless a PCR test for COVID-19 has been reported as negative within the previous 7 days or is acquired prior to randomization.

History of cancer within the last 5 years from screening, except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured.

Has screening laboratory test results meeting any of the following criteria:

Hemoglobin level \< 8.0 g/dL

WBC count \< 3.0 × 103/µL

Neutrophil count \<1.5 × 103/µL

Platelet count \< 100 × 103/µL

Total bilirubin level \>1.5 × ULN unless the test results are consistent with those for Gilbert's syndrome

AST or ALT values \> 2 × ULN

Any condition that, in the opinion of the investigator, could interfere with evaluation of the investigational product or interpretation of subject safety or confound the results of the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT06660732) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cardiac Sarcoidosis Treatment Options in Rochester, MN

If you're searching for cardiac sarcoidosis treatment options in Rochester, MN, this clinical trial (NCT06660732) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced cardiac sarcoidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cardiac sarcoidosis clinical trials near you to find additional studies recruiting in your area.

Cardiac Sarcoidosis Clinical Trial in Rochester, MN

Expert Care in Rochester

IRB Approved

No-Cost Care

Apply for This Rochester Location

Why Participate?

Simple Process

About This Cardiac Sarcoidosis Study in Rochester